Biogen Licenses Mitsubishi Tanabe Pharma's MT-1303 for Autoimmune Diseases

Biogen BIIB today announced an agreement to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications, from Mitsubishi Tanabe Pharma Corporation MTPZY. MT-1303 is an oral compound that targets the sphingosine 1-phosphate (S1P) receptor. Biogen is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn's disease, and other autoimmune indications. The compound has completed a successful Phase 2 clinical trial in MS and Biogen is evaluating a rapid development program in this indication. The company will also investigate indications in inflammatory bowel disease. Biogen will initiate a clinical trial in ulcerative colitis and may advance an existing program in Crohn's See full press release